Michael Chiu

Michael Chiu

Auto-generated profile, based on publicly available information

Michael Chiu

Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
KCKristin K Clemens
Kristin K Clemens
JEJaclyn Ernst
Jaclyn Ernst
TKTayyab Khan
Tayyab Khan
SRSonja Reichert
Sonja Reichert
QKQasim Khan
Qasim Khan
OIOK TRANSPLANT Investigators
OK TRANSPLANT Investigators

1 January 2024 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
GSGurleen Sahi
Gurleen Sahi
JRJennifer Reid
Jennifer Reid
LMLouise Moist
Louise Moist
MCMichael Chiu
Michael Chiu
AVAmanda Jean Vinson
Amanda Jean Vinson
KCKristin K Clemens
Kristin K Clemens
Background: Obesity has a major impact on health and health care, particularly in those with chronic kidney disease (CKD). Objective: The objective was to describe the prevalence, characteristics, and outcomes of people living with CKD and obesity (defined by a body mass index [BMI] ≥30 kg/m2) in Canada. Design: Population-based cohort study using linked administrative health data (ICES). Patients: Adults aged 18 year and older with CKD G1-5D who had a height and weight recorded during a visit to an academic hospital in London Ontario Canada, between January 2010 and December 2019. Measures: CKD as defined by CKD 3A or higher. BMI as defined by weight kg/m2. Methods: As a primary interest, we described the percentage of patients with CKD across different BMI categories (<25 kg/m2, BMI 25-29.9 kg/m2, and BMI ≥30 kg/m2), as well as their demographic and clinical profiles. As secondary interests, we followed patients until January 1, 2022 to summarize: (1) the percentage with CKD G3 who had kidney disease progression (50% decline from baseline estimated glomerular filtration rate [eGFR]) by BMI category, (2) the percentage with CKD G3-4 who developed kidney failure (initiation of maintenance dialysis or an eGFR of <15 mL/min/1.73 m2) by BMI category, (3) the percentage with CKD G4-G5D who received a kidney transplant by BMI category, and (4) post-transplant outcomes in those transplanted over the study period, by BMI category. We performed similar analyses across CKD risk categories. Results: Of the 198 151 patients included, the percentage with obesity defined by a BMI ≥30 kg/m2 increased from CKD G1 to CKD G4 (ie, 37% of those with CKD G1 had a BMI ≥30 kg/m2 vs 40.9% of CKD G4). In CKD G5D and CKD T, the prevalence of high BMI appeared to drop (only ~38% had a BMI ≥30 kg/m2 across groups). Across CKD categories, those with a BMI ≥30 kg/m2 appeared to have more comorbidities, use more health care resources, and have more socioeconomic disparities than those with lower BMIs. Although secondary outcome events were limited, those with G3-4 with a BMI ≥30 kg/m2 appeared to have a higher risk of CKD progression and those with CKD G5D with BMI ≥30 kg/m2 were less likely to receive transplant over the study period. Interestingly those transplanted with a BMI ≥30 kg/m2 appeared to have fewer post-transplant complications. We also observed an “obesity-paradox” in the risk of mortality, with high BMI appearing protective, particularly in the end stages of kidney disease. Limitations: We used BMI to capture obesity in this study but recognize its limitations as a measure of body composition. Secondary outcomes were descriptive and unadjusted due to small sample size and may have been subject to selection bias and confounding. Conclusions: Obesity defined by high BMI is highly prevalent in people with CKD, and patients have health, health care, and social disparity. Future studies to understand the impact of BMI on patients with CKD and how to individualize and manage BMI and obesity across the spectrum of CKD remain important.

12 October 2022 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
MCMichael Chiu
Michael Chiu
LMLouise Moist
Louise Moist
AAAhmed Al-Jaishi
Ahmed Al-Jaishi
AJArsh K. Jain
Arsh K. Jain
Background: Obesity is, directly and indirectly, linked to the progression of chronic kidney disease (CKD). However, nephrologists’ recognition of obesity and willingness to address and manage obesity are unknown. Objectives: The aim of this article is to investigate if obesity is recognized and documented in the clinical encounter and to examine nephrologists’ perceptions of obesity and comfort with weight loss management. Design: We conducted a 2-part study. Part I used a retrospective chart review and part II used an anonymous online survey of practicing nephrologists (n = 14) in our center. Setting: The study took place in the Multi-care Kidney Clinic (MCKC) at London Health Sciences Centre in London, Ontario, Canada. Patients: In part I, we conducted a retrospective chart review of 10 random patients with advanced CKD and obesity (body mass index [BMI] > 30 kg/m 2 ) from each of the nephrologists between January and December 2019. Methods: In part I, charts were assessed for documentation of obesity and/or a treatment plan (lifestyle counseling, pharmacologic intervention, and specialist referral). In part II, a survey completed by the nephrologists explored their current experience and perceptions of obesity and comfort with weight loss management. Responses were ranked on a 5-point Likert scale. Results: In all, 140 patient charts were reviewed. The median age was 69 (interquartile range [IQR] = 60-77) years, estimated glomerular filtration rate (eGFR) was 17 (IQR = 12-20) ml/min/1.73 m 2 , weight was 99 (IQR = 90-116) kg, and BMI was 36 (IQR = 33-40) kg/m 2 . Obesity with a BMI was documented in 36 (26%) charts, and only 2 (1%) documented a weight loss plan, which only included non-pharmacologic strategies. There were 13 survey responses (93% response rate). All nephrologists agreed that obesity negatively affects the health of patients with CKD. Twelve (92%) reported discussing obesity with patients, but none felt that they had time to treat it. All reported discussions of obesity would evoke a negative patient response, while 5 (38%) thought patients actually want to discuss obesity. Regarding treatment, 8 (62%) nephrologists felt comfortable with non-pharmacologic treatment, but only 1 respondent was comfortable with pharmacologic treatments. Twelve (92%) nephrologists thought patients should be referred to a specialist. Limitations: There was limited generalizability as this was a single center study. The BMI may reflect hypervolemia rather than body mass. Conclusion: In our study, nephrologists rarely document and manage obesity in patients with advanced CKD, despite their perception of treatment benefits. Improved outcomes of obesity management for patients with CKD will require increased knowledge and clinical tools to efficiently address obesity with patients.

12 January 2023 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
MCMichael Chiu
Michael Chiu
AGAmit X. Garg
Amit X. Garg
LMLouise Moist
Louise Moist
AJArsh K. Jain
Arsh K. Jain
Purpose of Review: Outpatient hyperkalemia is a common problem with potentially deadly consequences. Potassium level thresholds to treat outpatient hyperkalemia are unstandardized and variable, leaving health care providers to rely on their own clinical judgment. This narrative review highlights the challenges of outpatient hyperkalemia management and includes recommendations for future studies that may standardize treatment, improve patient outcomes, and optimize health care utilization. Sources of Information: PubMed, Google Scholar, and the reference lists of identified articles were used to include English, peer-reviewed studies and guidelines for this review. Methods: This narrative review examines outpatient hyperkalemia from both a laboratory and clinical perspective. In addition to peer-reviewed literature, guidelines and expert consensus statements were included to highlight the inconsistencies and paucity of evidence that health care providers rely on to make clinical decisions. Key Findings: There are multiple reasons why outpatient hyperkalemia management is both challenging and sub-optimal. Clinicians must discern if the potassium level result is accurate and, if so, does the result warrant referral to the emergency department. Factitious hyperkalemia, or falsely elevated potassium level results due to analytical errors, occurs frequently, but there are no ways to identify it other than for hemolyzed samples. Additionally, guidelines and expert panels are inconsistent on the thresholds for treatment and the management of hyperkalemia. Finally, there are inconsistencies between laboratories as to when and how providers are notified of results, and the suggested thresholds for urgent management. A study that integrates the expertise of clinical biochemists and clinicians is needed to inform evidence-based guidelines for the management of outpatient hyperkalemia. Limitations: This was a comprehensive review of what is known and what still needs to be understood for the management of outpatient hyperkalemia. A formal tool to assess the quality of the included studies was not used and selection bias may have occurred.

15 April 2025 in Kidney Medicine
Verified
Journal Article
Open access
KOKamel Omer
Kamel Omer
KCKristin K. Clemens
Kristin K. Clemens
YZYunxu Zhu
Yunxu Zhu
HLHeather LaPier
Heather LaPier
LMLouise Moist
Louise Moist
MCMichael Chiu
Michael Chiu
Obesity is associated with morbidity and mortality in people with chronic kidney disease (CKD). Identifying safe and effective nonpharmacologic and nonsurgical interventions to achieve a healthier body weight is essential. Scoping review of observational studies and randomized control trials. Adults aged ≥18 years with a body mass index (BMI) ≥30 kg/m2 and advanced CKD (category G3-G5D). Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews (PRISMA-ScR), we systematically searched 2 electronic databases (MEDLINE and Embase) for studies that examined the effect of nonpharmacologic and nonsurgical interventions for weight loss between January 2010-July 2024. Outcomes included weight loss and BMI. We also examined adherence, whether participants were involved in the design of the study, and adverse events. Two reviewers screened relevant citations and extracted study characteristics and outcomes. Discrepancies were resolved by a third reviewer. Study data were summarized descriptively following guidance from the PRISMA-ScR. Of the 2,453 citations, 17 met inclusion criteria (9 randomized controlled trials, 2 nonrandomized trials, 5 prospective cohort studies, and 1 retrospective cohort study) and included a total of 960 participants. Interventions included exercise programs, dietary therapy, and/or cognitive behavioral therapy with follow-up ranging from 3-12 months. It appeared that dietary intervention that promoted significant caloric restriction over the short term led to the most weight loss (average, 7 kg). Interventions with monitored coaching appeared helpful. No adverse events were reported. None of the studies involved participants as partners. Not all studies included participants’ estimated glomerular filtration rate or BMI category, and we may have included some without severe CKD or BMI ≥30 kg/m2. Programs encouraging very low-energy diets along with monitored coaching, may result in modest short-term weight loss. Patient views on these programs and their longer term success remain unclear.

21 May 2025 in Transplantation Direct
Verified
Journal Article
Open access
RZRoxaneh Msc Zaminpeyma
Roxaneh Msc Zaminpeyma
LMLouise Msc Moist
Louise Msc Moist
KCKristin K Clemens
Kristin K Clemens
MCMichael Chiu
Michael Chiu
JMJanet Rd Madill
Janet Rd Madill
AVAmanda Jean Vinson
Amanda Jean Vinson
Background.: The prevalence of obesity is increasing in both the general and kidney failure populations. Severe obesity (body mass index [BMI] ≥ 40 kg/m2) is considered by many centers to be a barrier to kidney transplantation (KT). Obesity is typically defined using BMI. Body surface area (BSA) is not considered, though may also be important. Methods.: We examined post-KT adverse outcomes associated with obesity defined using combined BMI-BSA parameters in a cohort of adult KT recipients (living/deceased donor) across the United States (Scientific Registry of Transplant Recipients: 2000–2017). Recipient obesity was defined as BMI ≥30 kg/m2, or BSA ≥1.94 m2 in women and ≥2.17 m2 in men. We used multivariable cox proportional hazards or logistic regression models as appropriate to assess the association between BMI-BSA-defined obesity with death-censored graft loss, all-cause graft loss, and delayed graft function. Results.: The final study included 242 432 patients; 77 556 (32.0%) had obesity based on BMI and 67 312 (28.6%) had obesity based on BSA. Compared to patients with a nonobese BMI and BSA, the adjusted risk of death-censored graft loss, all-cause graft loss, and delayed graft function was greatest when both BMI and BSA indicated obesity (adjusted hazard ratio 1.23, 95% confidence interval [CI]: 1.20-1.27, adjusted hazard ratio 1.09, 95% CI: 1.07-1.11, adjusted odds ratio 1.58, 95% CI: 1.53-1.63, respectively); a significantly greater risk than when BMI and BSA were discordant. Conclusions.: Currently only BMI is considered when evaluating obesity-related KT risk; however, combined BMI-BSA obesity may better identify individuals at high risk of poor outcomes posttransplant than BMI alone.